Publication:


abstract

amprenavir (APV) is a high affinity (0.15 nM) HIV-1 protease (PR) inhibitor. However, the affinities of the drug resistant protease variants V32I, I50V, I54V, I54M, I84V and L90M to amprenavir are decreased 3 to 30-fold compared to the wild-type. In this work, the popular molecular mechanics Poisson-Boltzmann surface area method has been used to investigate the effectiveness of amprenavir against the wild-type and these mutated protease variants. Our results reveal that the protonation state of Asp25/Asp25' strongly affects the dynamics, the overall affinity and the interactions of the inhibitor with individual residues. We emphasize that, in contrast to what is often assumed, the protonation state may not be inferred from the affinities but requires pK(a) calculations. At neutral pH, Asp25 and Asp25' are ionized or protonated, respectively, as suggested from pK(a) calculations. This protonation state was thus mainly considered in our study. Mutation induced changes in binding affinities are in agreement with the experimental findings. The decomposition of the binding free energy reveals the mechanisms underlying binding and drug resistance. Drug resistance arises from an increase in the Energetic contribution from the van der Waals interactions between APV and PR (V32I, I50V, and I84V mutant) or a rise in the energetic contribution from the electrostatic interactions between the inhibitor and its target (I54M and I54V mutant). for the V32I mutant, also an increased free energy for the polar solvation contributes to the drug resistance. For the L90M mutant, a rise in the van der Waals energy for APV-PR interactions is compensated by a decrease in the polar solvation free energy such that the net binding affinity remains unchanged. Detailed understanding of the molecular forces governing binding and drug resistance might assist in the design of new inhibitors against HIV-1 PR variants that are resistant against current drugs.

Related Articles
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
FEBS J. 2010
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
Shen CH, Wang YF, Kovalevsky AY, Harrison RW, Weber IT. FEBS J. 2010 Sep; 277(18):3699-714. Epub 2010 Aug 2.
Origin of decrease in potency of darunavir and two related antiviral inhibitors against HIV-2 compared to HIV-1 protease.
J Phys Chem B. 2012
Origin of decrease in potency of darunavir and two related antiviral inhibitors against HIV-2 compared to HIV-1 protease.
Kar P, Knecht V. J Phys Chem B. 2012 Mar 1; 116(8):2605-14. Epub 2012 Feb 14.
Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
J Phys Chem B. 2012
Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
Meher BR, Wang Y. J Phys Chem B. 2012 Feb 16; 116(6):1884-900. Epub 2012 Feb 3.
Review Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Drugs. 2005
Review Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C, Tribut O. Drugs. 2005; 65(5):633-59.
Review Darunavir: a review of its use in the management of HIV infection in adults.
Drugs. 2009
Review Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K, Perry CM, Keam SJ. Drugs. 2009; 69(4):477-503.